¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Abnormal results of function studies of central nervous system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
¿µ¹® digestive system ÇÑ±Û ¼ÒÈ­±â°èÅë
¼³¸í   
  ¸ÔÀº À½½ÄÀÇ ºÐÇØ, ¼ÒÈ­, Èí¼ö¿¡ °ü°èµÈ Àå±â¸¦ ÅëÄªÇØ¼­ ºÎ¸£´Â ¸».
¿µ¹® cardiovascular system ÇÑ±Û ½ÉÀåÇ÷°ü°è
¼³¸í   
  ½ÅüÀÇ Ç÷¾×¼øÈ¯À» ´ã´çÇϴ ±â°ü. Áï ½ÉÀå°ú Ç÷°üÀ» ÅëÄªÇØ¼­ À̸£´Â ¸»ÀÌ´Ù.
¿µ¹® TNM staging system ÇÑ±Û Á¾¾çº´±âºÐ·ù°èÅë
¼³¸í   
  Á¾¾çÀÇ º´±â(stage)¸¦ °áÁ¤Çϴ ÇÑ ¹æ¹ý.
  
  T´Â Tumor(Á¾¾ç)¸¦ ¶æÇϸ砿ø¹ßº´ÅÍÀÇ Å©±â, ÁÖÀ§Á¶Á÷À¸·ÎÀǠħÀ±Á¤µµ µî¿¡ µû¶ó T1, T2, T3, T4(¼ýÀÚ°¡ ³ôÀ» ¼ö·Ï ÁÖÀ§·Î Ä§À±ÀÌ ¸¹´Ù) µîÀ¸·Î ³ª´«´Ù.
  
  NÀº Node(¸²ÇÁÀý)¸¦ ¶æÇϸç Ä§¹üµÈ ¸²ÇÁÀýÀÇ °¹¼ö, Å©±â, À§Ä¡ µî¿¡ µû¶ó N1, N2, N3 µîÀ¸·Î ³ª´«´Ù.
  
  MÀº Metastasis(ÀüÀÌ)¸¦ ¶æÇϸ砿ø°ÝÀüÀÌÀÇ À¯¹«¿¡ µû¶ó M0, M1 µîÀ¸·Î ³ª´«´Ù.
  
  ÀÌ»óÀÇ ¹æ¹ýÀ¸·Î T, N, MÀÌ °áÁ¤µÇ¸é À̵éÀ» Á¶ÇÕÇÏ¿© ÃÖÁ¾ÀûÀΠº´±â¸¦ °áÁ¤ÇÑ´Ù. ÀÌ·¸°Ô °áÁ¤µÈ º´±â´Â Ä¡·á ¹æÄ§ °áÁ¤°ú ¿¹ÈÄ ÆÇ´Ü¿¡ ¸Å¿ì Áß¿äÇÏ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • vital function
    »ý¸í±â´É
  • central
    Áß½É-, ÁßÃß-
  • central amaurosis
    ÁßÃß¼ºÈæ¾Ï½Ã
  • central aphasia
    ÁßÃß¾ð¾î»ó½ÇÁõ, ÁßÃ߽ǾîÁõ
  • central artery
    Á߽ɵ¿¸Æ
  • central ataxia
    ÁßÃß½ÇÁ¶
  • central attachment
    Á߽ɺÎÂø
  • central auditory processing disorder
    ÁßÃßû°¢Ã³¸®Àå¾Ö
  • central callus
    Á߽ɾֹú»À, Á߽ɰ¡°ñ
  • central canal
    Á߽ɰü
  • central cataract
    Á߽ɹ鳻Àå
  • central chemoreceptor
    ÁßÃßÈ­Çмö¿ëü
  • central cord syndrome
    Áß½Éô¼öÁõÈıº
  • central core disease
    Áß½ÉÇÙº´, Áß½ÉÄھ
  • central cyanosis
    Áß½Éû»öÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • reflex function
    ¹Ý»ç±â´É
  • somatosensory function
    ¸ö°¨°¢±â´É
  • survival function
    »ýÁ¸ÇÔ¼ö
  • vegetative function
    Áõ½Ä´É
  • vital function
    »ý¸í±â´É
  • liver function test
    °£±â´É°Ë»ç
  • pulmonary function test
    Æó±â´É°Ë»ç
  • renal function test
    ÄáÆÏ±â´É°Ë»ç, ½ÅÀå±â´É°Ë»ç
  • respiratory function test
    È£Èí±â´É°Ë»ç
  • righting function test
    ¹Ù·Î¼­±â±â´É°Ë»ç
  • vestibular function test
    ÀüÁ¤±â´É°Ë»ç, ¾È¶ã±â´É°Ë»ç
  • central amaurosis
    ÁßÃßÈæ¾Ï½Ã
  • central aphasia
    ÁßÃß¾ð¾î»ó½ÇÁõ
  • central artery
    Á߽ɵ¿¸Æ
  • central ataxia
    ÁßÃßÁ¶È­¿îµ¿ºÒ´É
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • homeostatic function
    Ç×»ó¼º ±â´É(ѦÒö).
  • immunologic function
    ¸é¿ª±â´É.
  • phonatory function
    ¹ß¼º±â´É(¡­Ñ¦Òö).
  • phonatory function
    ¹ß¼º±â´É
  • platelet function disorders
    Ç÷¼ÒÆÇ±â´ÉÀÌ»óÁúȯ
  • postictal disturbance of cerebral function
    ¹ßÀÛÈÄ´ë³ú±â´ÉÀå¾Ö(Û¡íÂý­ÓÞÒà ѦÒöî¡äô).
  • power function graph
    Èû±â´É±×·¡ÇÁ
  • primitive function
    ¿ø½Ã±â´É(ÊÙË»ËÀ).
  • probability function
    È®·üÇÔ¼ö(ÊṴ̀Ëà).
  • pulmonary function test
    Æó±â´É°Ë»ç (¡­ËþÞÛ).
  • radial function
    µ¿°æÇÔ¼ö(ÔÑÌÓùÞâ¦).
  • regular function
    Á¤»ó±â´É(ïáßÈѦÒö).
  • renal function
    ½Å±â´É(ãìѦÒö).
  • renal function testing
    ½Å±â´É°Ë»ç
  • ABH system
    ABH °è(Åë)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • abnormal retinal correspondance
    ÀÌ»ó¸Á¸·´ëÀÀ
  • abnormal shape
    ÀÌ»óÇüÅÂ
  • abnormal temperature
    ÀÌ»ó¿Âµµ, ÀÌ»óü¿Â(~ü¿Â).
  • abnormal uterine bleeding
    ÀÌ»óÀÚ±ÃÃâÇ÷(~í­Ïàõóúì).
  • abocclusion =abnormal occlusion
    °³±³(ËÒÎá).
  • hemoglobinopathy =abnormal hemoglobin disease
    Ç÷»ö¼Òº´Áõ.
  • subtotal abnormal shape
    ºÎºÐÀÌ»óÇüÅÂ
  • total abnormal shape
    ÀüüÀÌ»óÇüÅÂ
  • transverse tubular system =T system
    ÀÌ ·Î¼Ò°ü°èÅë, T°è(¡­Í§), ȾÇà¼Ò°ü°è(üôú¼á³Î·Í§) ±Ù(ÐÉ)ÀÇ .
  • breakdown nervous
    ½Å°æ¼è¾à
  • intrinsic nervous plexus
    º®¼Ó½Å°æ¾ó±â
  • myenteric nervous plexus
    ±ÙÀ°Ãþ½Å°æ¾ó±â
  • nervous asthenopia
    ½Å°æ(¼º)´«ÇÇ·Î
  • nervous axillaris ; axillary nerve
    °Üµå¶û½Å°æ, ¾×¿Í½Å°æ(äýèÀãêÌè).
  • nervous disease
    ½Å°æÁúȯ(~òðü´).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Central part
    Á߽ɺκÐ
    [¿¾ ¿ë¾î] Á߽ɺÎ
  • Central attachment
    Á߽ɺÎÂø
    [¿¾ ¿ë¾î] Á߽ɺÎÂø
  • Central insertion
    Á߽ɺÎÂø
    [¿¾ ¿ë¾î] Á߽ɺÎÂø
  • Central fiber
    Á߽ɼ¶À¯
    [¿¾ ¿ë¾î] Á߽ɼ¶À¯
  • Central lobule
    Á߽ɼҿ±
    [¿¾ ¿ë¾î] ¼Ò³úÁ߽ɼҿ±
  • Ala of central lobule
    Á߽ɼҿ±³¯°³
    [¿¾ ¿ë¾î] Á߽ɼҿ±ÀÍ
  • Central thalamic radiations
    Á߽ɽûóºÎê»ì
    [¿¾ ¿ë¾î] ±Ã½É½Ã»ó¹æ»ç
  • Central thalamic radiations
    Á߽ɽûóºÎê»ì
    [¿¾ ¿ë¾î] Áß½É½Ã»ó¹æ»ç
  • Central gelatinous substance
    Á߽ɾƱ³Áú
    [¿¾ ¿ë¾î] Á߽ɱ³¾çÁú
  • Central fovea
    Á߽ɿÀ¸ñ
    [¿¾ ¿ë¾î] Á߽ɿÍ
  • Central vein
    Áß½ÉÁ¤¸Æ
    [¿¾ ¿ë¾î] Áß½ÉÁ¤¸Æ
  • Central veins
    Áß½ÉÁ¤¸Æ
    [¿¾ ¿ë¾î] Áß½ÉÁ¤¸Æ
  • Central intermediate substance
    Áß½ÉÁß°£È¸»öÁú
    [¿¾ ¿ë¾î] Áß°£ÁúÁ߽ɺÎ
  • Central nucleus
    Áß½ÉÇÙ
    [¿¾ ¿ë¾î] Áß½ÉÇÙ
  • Central gray (substance)
    Áß½Éȸ»öÁú
    [¿¾ ¿ë¾î] Áß½Éȸ¹éÁú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Kovats retention index system
    ÄÚ¹ÙÆ® ü·ù(ôò׺) Áö¼ö(ò¦â¦)½Ã½ºÅÛ
  • K system
    K ½Ã½ºÅÛ
  • leiotonin system
    ¶óÀÌ¿ÀÅä´Ñ ½Ã½ºÅÛ
  • MN blood group system
    MN½Ä(ãÒ)Ç÷¾×Çü(úìäûúþ)
  • model system
    ¸ðµ¨½Ã½ºÅÛ
  • multienzyme system
    ´ÙÈ¿¼Ò(Òýý£áÈ)½Ã½ºÅÛ
  • multisubstrate enzyme system
    ´Ù±âÁúÈ¿¼Ò(ÒýѨòõý£áÈ) ½Ã½ºÅÛ
  • open-circuit system
    °³¹æÈ¸·Î(ËÒÛ¯üÞÖØ) ½Ã½ºÅÛ
  • open system
    °³¹æ(ËÒÛ¯) ½Ã½ºÅÛ
  • optical system
    ±¤(ÎÃ) ½Ã½ºÅÛ
  • phosphotransferase system
    Æ÷½ºÆ÷Æ®¶õ½ºÆÛ·¹À̽º ½Ã½ºÅÛ
  • protein-synthesizing system
    ´Ü¹éÁú ÇÕ¼º(Ó±ÛÜòõùêà÷) ½Ã½ºÅÛ
  • repressible system
    ¾ïÁ¦¼º ½Ã½ºÅÛ
  • restriction-modification system
    Á¦ÇÑ ¼ö½Ä(áóãÞ) ½Ã½ºÅÛ
  • reticuloendothelial system
    ¸Á»ó³»ÇÇ(ØÑßÒÒ®ù«) ½Ã½ºÅÛ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SEER Surveillance Epidemiology and End Results [Program]
ISIS image selected in vivo spectroscopy; imaging science and information system; information system-imag...
PNS Peripheral Nervous System;
ANS acanthion; American Nutrition Society; 8-anilino-1-naphthalene-sulfonic acid; anterior nasal spine; ...
GANS granulomatous angiitis of the nervous system
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AIM abnormal involuntary movement
AUB Abnormal Uterine Bleeding
Awd Abnormal wing disc
TAM Transient abnormal myelopoiesis
MFO mixed function oxidase system
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cervical function
    °æÃß ±â´É
  • chemotactic function
    È­ÇÐ ÁÖ¼º ±â´É
  • colonic function
    ´ëÀå ±â´É
  • convex function
    º¼·Ï ÇÔ¼ö
  • executive function
    ½ÇÇ༺ ±â´É
  • function
    ±â´É
    ¾î¶² Àå±â³ª ºÎºÐÀÇ Æ¯¼öÇϰí Á¤»óÀûÀÎ ¶Ç´Â °íÀ¯ÇÑ »ý¸®Àû Ȱµ¿.
  • function modification
    ±â´É º¯Çü
  • function of saliva
    Ÿ¾×ÀÇ ±â´É
  • function test
    ±â´É ½ÃÇè
  • immunologic function
    ¸é¿ª ±â´É
  • labyrinthine function
    ¹Ì·Î ±â´É
  • language function
    ¾ð¾î ±â´É
  • logarithmic function
    ·Î±× ÇÔ¼ö
    ÇØ¼®ÇÐ ¿ë¾î. a¸¦ 1ÀÌ ¾Æ´Ñ ¾çÀÇ »ó¼ö¶ó°í ÇÒ ¶§, µÎ º¯¼ö x¿Í y »çÀÌ¿¡ a=xÀÎ °ü°è°¡ ÀÖÀ¸¸é y´Â a¸¦ ¹ØÀ¸·Î ÇÏ´Â xÀÇ ·Î±× ÇÔ¼ö¶ó Çϰí, y£½log x·Î ³ªÅ¸³½´Ù.
  • mixed function oxidase
    È¥ÇÕ ±â´É ¿Á½Ãµ¥À̽º
  • myocardial function
    ½É±Ù ±â´É
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
combination studies <pharmacology> Studies in which a new drug is evaluated in combination with existing drugs.
(09 Jan 1998)
multicenter studies Controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children.
(12 Dec 1998)
multivariate studies The use of statistical techniques for the simultaneous investigations of the influence of several variables.
(05 Mar 2000)
preclinical studies <pharmacology> Studies in which a drug is tested on animals and in other non-human test systems. Safety information from such studies are used to support an investigational new drug application.
(14 Nov 1997)
sampling studies Studies in which a number of subjects are selected from all subjects in a defined population. Conclusions based on sample results may be attributed only to the population sampled.
(12 Dec 1998)
prospective studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
(12 Dec 1998)
his bundle studies <cardiology> This test studies the electrical activity of the bundle of HIS.
The bundle of HIS is a group of electrical fibres in the heart that are responsible for transmitting the electrical impulses which generate a normal cardiac contraction. This test may be performed in cases of cardiac arrhythmias, to locate a specific area responsible for a conduction defect and to determine the need for cardiac pacemaker placement.
The test involves the passage of a an electrode tipped catheter into the heart. This catheter is usually threaded through a neck, arm or chest vein. Measurements of the HIS bundle can then be performed while standard ECG leads are placed on the arms and legs.
This test carries a small risk of bleeding, arrhythmias, embolism, heart attack and stroke. It is performed by a specially trained cardiologist.
(27 Sep 1997)
immunofluorescent studies <technique> A special assay that relies on the production of measurable fluorescent light. An immunofluorescent tagged antibody interacts and binds with an antigen allowing an indirect measurement of its concentration.
(27 Sep 1997)
intervention studies Epidemiologic investigations designed to test a hypothesised cause-effect relation by modifying the supposed causal factor(s) in the study population.
(12 Dec 1998)
intracardiac electrophysiology studies <cardiology, investigation> A special study that involves the placement of electrodes inside the heart to map the electrical characteristics of the heart.
This study is carried out in a specially equipped lab and is similar to a cardiac catheterisation procedure. Electrodes are placed inside the heart via a catheter placed into a vein. The electrodes are positioned near the heart's conduction system and an electrical map of the heart can be determined.
This test is often performed in those where a life-threatening cardiac arrhythmia is a problem. The location and characteristics of an arrhythmia can be determined, thus guiding medical management of the problem. Patients with Wolf Parkinson White syndrome or sick sinus syndrome may have this test as part of their evaluation.
(27 Sep 1997)
organizational case studies Descriptions and evaluations of specific health care organizations.
(12 Dec 1998)
time and motion studies The observation and analysis of movements in a task with an emphasis on the amount of time required to perform the task.
(12 Dec 1998)
electrophysiological studies <investigation> A special study that involves the placement of electrodes inside the heart to map the electrical characteristics of the heart.
This study is carried out in a specially equipped lab and is similar to a cardiac catheterisation procedure. Electrodes are placed inside the heart via a catheter placed into a vein. The electrodes are positioned near the heart's conduction system and an electrical map of the heart can be determined. This test is often performed in those where a life-threatening cardiac arrhythmia is a problem.
The location and characteristics of an arrhythmia can be determined, thus guiding medical management of the problem. Patients with Wolf Parkinson White syndrome or sick sinus syndrome may have this test as part of their evaluation.
Acronym: EPS
(14 Mar 2000)
epidemiologic studies Studies designed to examine associations, commonly, hypothesised causal relations. They are usually concerned with identifying or measuring the effects of risk factors or exposures. The common types of analytic study are case-control studies, cohort studies, and cross-sectional studies.
(12 Dec 1998)
evaluation studies Studies determining the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. For drugs and devices, clinical trials, drug evaluation, and drug screening are available.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • system
    Á¶Á÷,°èÅë,¹æ½Ä
  • Bertillon system
    º£¸£Æ¼¿ë½Ä ¹üÀνĺ°¹ý(Áö¹®À» Áß½Ã)
  • CAPTAIN System
    ĸƾ½Ã½ºÅÛ(°¡Á¤ÀÇ À¯¼± ÅÚ·¹ºñÀü¿¡ÀÇ Á¤º¸ Á¦°ø ½Ã½ºÃÀ,»óÇ¥¸í)
  • Continental System
    ´ë·úºÀ¼â(1806³â NapoleonÀÇ ¿µ±¹¿¡ ´ëÇÑ)
  • Copernican system
    ÄÚÆä¸£´ÏÄí½º¼³(ü°è);(žçÁ߽ɼ³,Áöµ¿¼³)
  • Dewey classification system
    µµ¼­ÀÇ µàÀÌ 10Áø ºÐ·ù¹ý
  • Dolby system
    µ¹ºñ¹æ½Ä(³ìÀ½ Å×ÀÌÇÁÀÇ ÀâÀ½À» ÁÙÀÌ´Â ¹æ¹ý)
  • Doppler Lidar System
    µµÇ÷¯ È¿°ú¸¦ ÀÌ¿ëÇÑ ±¤ÇÐ½Ä ¼Óµµ°è
  • European Monetary System
    À¯·´ ÅëÈ­ Á¦µµ
  • Federal Reserve System
    ¿¬¹æÁغñÁ¦µµ
  • Gary system
    °Ô¸®½Ä Çб³ Á¦µµ
  • Harvard system
    ÇϹöµå ½Ã½ºÅÛ(Çмú¼­,ÀâÁöÀÇ Âü°í ¹®Çå Ç¥½Ã¹ýÀÇ Çϳª)
  • Information Network System
    °íµµ Á¤º¸ Åë½Å ½Ã½ºÅÛ
  • Montessori method(system)
    (ÀÌÅ»¸®¾ÆÀÇ ¿©¼º ±³À°°¡ À̸§¿¡¼­) ¸óÅ×¼Ò¸®½Ä ±³À°¹ý(¾Æµ¿ÀÇ ÀÚÁÖ¼ºÀÇ ½ÅÀåÀ» Áß½ÃÇÑ ±³À°¹ý) m`
  • PA system
    =PUBLICADDRESS SYSTEM
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á